Age-related macular degeneration (AMD), a leading cause of blindness worldwide, is as prevalent as cancer in industrialized nations. Most blindness in AMD results from invasion of the retina by choroidal neovascularisation (CNV). Here we show that the eosinophil/mast cell chemokine receptor CCR3 is specifically expressed in choroidal neovascular endothelial cells in humans with AMD, and that despite the expression of its ligands eotaxin-1, -2 and -3, neither eosinophils nor mast cells are present in human CNV. Genetic or pharmacological targeting of CCR3 or eotaxins inhibited injury-induced CNV in mice. CNV suppression by CCR3 blockade was due to direct inhibition of endothelial cell proliferation, and was uncoupled from inflammation because it occurred in mice lacking eosinophils or mast cells, and was independent of macrophage and neutrophil recruitment. CCR3 blockade was more effective at reducing CNV than vascular endothelial growth factor A (VEGF-A) neutralization, which is in clinical use at present, and, unlike VEGF-A blockade, is not toxic to the mouse retina. In vivo imaging with CCR3-targeting quantum dots located spontaneous CNV invisible to standard fluorescein angiography in mice before retinal invasion. CCR3 targeting might reduce vision loss due to AMD through early detection and therapeutic angioinhibition.
Age-related macular degeneration (AMD), a leading cause of blindness worldwide, is as prevalent as cancer in industrialized nations. Most blindness in AMD results from invasion of the retina by choroidal neovascularisation (CNV). Here we show that the eosinophil/mast cell chemokine receptor CCR3 is specifically expressed in choroidal neovascular endothelial cells in humans with AMD, and that despite the expression of its ligands eotaxin-1, -2 and -3, neither eosinophils nor mast cells are present in human CNV. Genetic or pharmacological targeting of CCR3 or eotaxins inhibited injury-induced CNV in mice. CNV suppression by CCR3 blockade was due to direct inhibition of endothelial cell proliferation, and was uncoupled from inflammation because it occurred in mice lacking eosinophils or mast cells, and was independent of macrophage and neutrophil recruitment. CCR3 blockade was more effective at reducing CNV than vascular endothelial growth factor A (VEGF-A) neutralization, which is in clinical use at present, and, unlike VEGF-A blockade, is not toxic to the mouse retina. In vivo imaging with CCR3-targeting quantum dots located spontaneous CNV invisible to standard fluorescein angiography in mice before retinal invasion. CCR3 targeting might reduce vision loss due to AMD through early detection and therapeutic angioinhibition.
AMD affects 30-50 million people globally, with approximately 90% of severe vision loss attributed to CNV 1 . The worldwide prevalence of CNV is expected to double in the next decade owing to population ageing. Targeting the pro-angiogenic cytokine VEGF-A has been validated in patients with CNV [2] [3] [4] . However, substantial improvement of vision only occurs in one-third of patients treated with VEGF-A antagonists, and one-sixth of treated patients still progress to legal blindness. Moreover, safety concerns about the continual blockade of VEGF-A, which is constitutively expressed in the normal adult human retina 5 , are emerging 6, 7 . Thus, treatment strategies on the basis of more specific targeting of CNV are desirable. However, no molecular marker specific for human CNV has yet been reported.
CCR3 expression restricted to CNV in human eyes
In our studies examining the role of chemokines in angiogenesis, we discovered that CCR3 (also known as CD193)-a chemokine receptor best known for its role in promoting eosinophil and mast cell trafficking 8 -was expressed in human choroidal endothelial cells (CECs) only in the context of CNV due to AMD, and not in other non-proliferating or proliferating choroidal vasculature ( Fig. 1 ). Immunolocalization studies showed that CCR3 was expressed in CECs of all examined specimens of surgically excised choroidal neovascular tissue from patients with AMD (18 out of 18) who had not received prior AMD treatment (Fig. 1a, b and Supplementary Fig. 1 ). In contrast, CCR3 was not expressed in CECs in the choroid of any patients with early (atrophic) AMD (0 out of 10), or in age-matched patients without AMD (0 out of 10) ( Fig. 1c, d ). CCR3 was also not immunolocalized in surgically excised tissue from patients with epiretinal fibrotic membranes (0 out of 6), or in CECs in patients with choroidal melanoma (0 out of 8) ( Fig. 1e , f). Collectively, these data point to a highly specific pattern of CCR3 expression (P 5 7 3 10 214 , exact contingency table test) in CECs in neovascular AMD. Furthermore, we identified the expression of the CCR3 ligands eotaxin-1 (also known as CCL11), -2 (CCL24), and -3 (CCL26) in all examined specimens of surgically excised choroidal neovascular tissue from patients with AMD who had not received previous AMD treatment ( Fig. 1g-j ), suggesting that the eotaxin-CCR3 axis could be involved in this disease state. Notably, despite the abundance of eotaxins, eosinophils and mast cells were not identified in human CNV ( Supplementary Fig. 2 ), consistent with earlier findings 9 .
CCR3 stimulation promotes CEC migration and proliferation
The best determined pathological function of CCR3 so far has been its role in allergic diseases, such as asthma [10] [11] [12] [13] [14] and eosinophilic esophagitis 15 . There is a single report of its direct role in angiogenesis 16 . CNV. a, b, Immunofluorescence shows that CCR3-receptor expression (green) colocalizes with CD31 1 -expressing (red) blood vessels in surgically excised human AMD choroidal neovascular tissue (CNVM). Nuclei were stained blue with 4,6-diamidino-2-phenylindole (DAPI). The specificity of CCR3 staining in a is confirmed by the absence of staining with an isotype control IgG (green) in b. Individual red and green fluorescence channels are shown in Supplementary Fig. 1 . c, d, CCR3 is not immunolocalized in CD31 1 (red) blood vessels (white arrowheads) in the choroid of patients with atrophic AMD who do not have CNV (c), or in aged patients without AMD (d). Autofluorescence of RPE (white arrow) and Bruch's membrane (asterisks) overlying choroid are seen. e, f, CCR3 is not expressed in surgically excised avascular retinal fibrosis tissue (e) or in the blood vessel of choroidal melanoma (f). g-j, Immunohistochemistry (golden brown reaction product) shows expression of CCL11 (g), CCL24 (h), and CCL26 (i) in surgically excised AMD choroidal neovascular tissue, primarily in the stroma (red arrowheads) but also in the blood vessels (yellow arrows). The specificity of staining is confirmed by the absence of staining with isotype control IgG (j). Scale bars, 10 mm. involved in angiogenesis 17, 18 , such actions are considered minor or isolated. Therefore, we studied the effects of CCR3 modulation on angiogenesis in vitro and in vivo. Neutralizing anti-CCR3 antibodies inhibited the tube formation of primary human CECs cultured in Matrigel in vitro ( Fig. 2a ). In an experimental model of CNV induced by laser injury in wild-type mice [19] [20] [21] [22] [23] [24] , neutralizing anti-CCR3 antibodies reduced the fraction of CECs in vivo that was in the proliferative state of the cell cycle ( Fig. 2b ). Consistent with this finding, each of the three eotaxins stimulated human CEC proliferation ( Fig. 2c ). Cytoskeletal rearrangement through polymerization of monomeric actin to microfilamentous F-actin, which is essential for eosinophil chemotaxis induced by the eotaxins, is also critical in angiogenic migration of endothelial cells. Stimulation of human CECs with any of the three eotaxins induced a rapid polymerization of actin molecules ( Fig. 2d, e ). All three eotaxins also activated RAC1 ( Supplementary Fig. 3 ), a small GTPase that is critical in regulating endothelial cell spreading and migration, and promoted human CEC migration in a dose-dependent fashion (Fig. 2f ). Collectively, these data demonstrate that CCR3 activation can promote several steps of angiogenesis. The expression of CCR3 on CECs in vivo is confined to choroidal neovascular tissues; however, in vitro, human CECs responded to CCR3 ligands. This might be owing to the presence of several CNV-promoting growth factors in the culture medium.
Although eosinophils and mast cells have been reported to be

CCR3 receptor or ligand antagonism inhibits CNV
We studied the in vivo effects of CCR3 targeting in a mouse model of CNV induced by laser injury 22 , which is the most widely used animal model of this disease. A single intraocular administration of either CCR3-neutralizing antibodies or a small molecule CCR3 receptor antagonist ((S)-methyl-2-naphthoylamino-3-(4-nitrophenyl)propionate; SB328437) suppressed laser-injury-induced CNV in wildtype mice in a dose-dependent fashion (Fig. 3a-c) . CNV was also diminished in Ccr3 2/2 mice 25 compared to wild-type mice (Fig. 3d ). The specificity of pharmacological CCR3 blockade was confirmed by demonstrating that CNV was not reduced in Ccr3 2/2 mice by CCR3neutralizing antibodies or a CCR3 receptor antagonist (116 6 7% and 109 6 16% of control, respectively; n 5 5; P . 0.1). CCL11 and CCL24, the principal mouse ligands for CCR3, were markedly increased soon after laser injury, and immunolocalized to the retinal pigmented epithelium (RPE), which is adjacent to CECs (Fig. 3e, f ). Also, human RPE cells synthesized all three eotaxins ( Supplementary  Fig. 4 ), implicating these cells, which are abundantly interspersed in CNV 9 , as a source of CCR3 ligands in CNV. Genetic ablation of either Ccl11 (ref. 26) or Ccl24 (ref. 12) reduced CNV, whereas the neovascular response in Ccl11 2/2 Ccl24 2/2 mice 12 was suppressed to a greater extent than in either of the single knockout mice, suggesting cooperation between these two ligands in this system (Fig. 3g) . A single intraocular administration of neutralizing antibodies against CCL11 or CCL24 also suppressed CNV in wild-type mice (Fig. 3h, i) , validating these CCR3 ligands as anti-angiogenic targets. Together, these data demonstrate that CCR3 activation is essential for in vivo angiogenesis in the most widely used preclinical model of neovascular AMD.
CCR3-driven angiogenesis uncoupled from inflammation
We sought to determine whether CCR3 targeting reduced CNV solely by anti-angiogenic mechanisms, or whether anti-inflammatory mechanisms were also involved. Neither eosinophils nor mast cells (defined as CCR3 hi CD3 2 CD117 int CD49d 1 and CCR3 int CD3 2 CD117 hi CD49d 1 cells, respectively) were recruited to the choroid after laser injury, as monitored by flow cytometry ( Supplementary  Fig. 5 ). Furthermore, the CNV response in eosinophil-deficient Ddbl GATA mice 11 (containing a deletion of the double GATA site) and mast-cell-deficient Kit W-v /Kit W-v mice 27 was not different from the response in wild-type mice (Fig. 3j ). Moreover, intraocular administration of neutralizing anti-CCR3 antibodies reduced CNV in Ddbl GATA or Kit W-v /Kit W-v mice to the same extent as in wild-type mice. Thus, although eosinophils and mast cells have been reported to be capable of driving angiogenesis in other systems 17, 18 , both cell types are dispensable in the development of experimental CNV. Although neutrophil and macrophage infiltration are crucial for the development of experimental CNV 23,28 , CCR3-receptor targeting did not affect recruitment of either inflammatory cell type (defined as Gr-1 1 F4/80 2 and F4/80 1 CD11c 2 cells, respectively; Supplementary  Fig. 5 ). Therefore, the angioinhibitory effect of CCR3 blockade in this model is a direct anti-vascular effect, and does not seem to involve modulation of cellular inflammation. The mechanisms underlying the paucity of eosinophils and mast cells in CNV remain to be defined. One potential explanation could be the expression of CXCL9 in CNV, which blocks eotaxin-induced CCR3-mediated eosinophil recruitment ( Supplementary Fig. 6 ) 29, 30 . Other mechanisms influencing adhesion or mobilization of these leukocytes might also be operative.
CNV bioimaging by CCR3 targeting
Because invasion of the retina by CNV results in morphological and functional disruption of the retina, early detection of CNV is desirable; indeed, detection of CNV before retinal invasion would be ideal. CNV that has breached the retina can be detected by fluorescein angiography. However, this diagnostic modality cannot detect CNV before it has invaded the retina, that is, when it is still limited to the choroid. Yet, post-mortem histopathological studies have shown that substantial numbers of patients in whom fluorescein angiography does not reveal the presence of CNV nevertheless have CNV that has not yet invaded the retina 31 . Therefore, we explored whether CCR3-targeted bioimaging using anti-CCR3 Fab antibody fragments ( Supplementary  Fig. 7 ) conjugated to quantum dots (QDot-CCR3 Fab) could detect CNV before it became clinically evident. We previously described the spontaneous development of CNV in senescent mice deficient in monocyte chemoattractant protein-1 (CCL2, also known as MCP-1) or its CCR2 receptor 32 . Similar pathology occurs at a younger age in Ccl2 2/2 Ccr2 2/2 mice (J.A., M.E.K., J.Z.B., H.K. and B.J.R., unpublished data). These mice also undergo outer retinal degeneration rapidly ( Supplementary Fig. 8 ). We tested whether fundus angiography after intravenous injection of QDot-CCR3 Fab could detect subretinal CNV in these mice. QDot-CCR3 Fab angiography demonstrated hyperfluorescent signals in regions of the fundus of these mice that were silent on fluorescein angiography ( Fig. 4a, b) . The specificity of CCR3 targeting was confirmed by the absence of hyperfluorescent signals in Ccl2 -/-Ccr2 -/mice injected with QDot-isotype Fab, and in wild-type mice injected with QDot-CCR3 Fab ( Fig. 4b and Supplementary Fig. 9 ). Histological examination of these areas showed proliferating (Ki67 1 ) CCR3 1 blood vessels in the choroid that had not yet invaded the retina, along with the accumulation of QDot-CCR3 Fab in these vessels ( Fig. 4c-g) . These data provide proof-of-principle that CCR3-targeted bioimaging can detect subclinical CNV before it disrupts the retina and causes vision loss. of the fundus taken after intravenous injection of sodium fluorescein in wild-type and Ccl2 2/2 Ccr2 2/2 mice show normal retinal vascular filling but no areas of hyperfluorescence indicative of CNV. b, After intravenous injection of QDot-CCR3 Fab in the same Ccl2 2/2 Ccr2 2/2 mouse shown in a, focal branching choroidal hyperfluorescence was visualized (arrow) at 1 h in the same area that was not hyperfluorescent during fluorescein angiography (arrowhead in a). The intensity of this hyperfluorescence (shown in red pseudocolour in the inset) increased, attaining a peak at 4 h, and then declined in intensity but still persisted at 12 h. Corresponding images of QDot-Isotype Fab angiography showed no hyperfluorescence. c-e, The region corresponding to the area of hyperfluorescence seen on QDot-CCR3 Fab angiography in b contained several CD31 1 blood vessels in the choroid (Ch) that were proliferating (Ki67 1 ; arrows) and had not invaded the retina (Ret). Individual green (CD31 1 , c), red (Ki67 1 , d), and merged (e) fluorescence channel images are shown. Nuclei were stained with DAPI (blue). Arrows point to proliferating endothelial cells. The inset in e shows Ki67 1 CD31 1 cells in higher magnification. f, QDot-CCR3 Fab hyperfluorescent areas were localized to areas of subretinal CNV with CCR3 1 endothelial cells. g, The QDot label was visualized within CD31 1 vasculature of subretinal CNV lesions. Images are representative of six independent experiments. Scale bars, 10 mm (c-g).
CCR3 targeting is superior to VEGF-A targeting By comparing CCR3 targeting to VEGF-A targeting, the most effective approved treatment for human CNV, we found that CCR3-neutralizing antibodies were more effective than VEGF-Aneutralizing antibodies (68 6 3% versus 57 6 4%) at inhibiting laser-induced CNV in mice ( Supplementary Fig. 10 ). In the laserinjury model, CCR3 neutralization did not change VEGF-A levels in the RPE/choroid and VEGF-A blockade did not change CCR3 expression on CECs ( Supplementary Fig. 11 ): these two pathways seem to not be directly coupled. Repeated intravitreous administration of anti-VEGF-A antibodies resulted in anatomical and functional damage to the retina in wild-type mice ( Supplementary  Fig. 12 ), consistent with earlier reports that anti-VEGF-A therapy induces dysfunction in and damage to the inner and outer murine retina 6, 7 . These effects were modest at a dose of anti-VEGF-A antibodies that suppressed mouse CNV, but more pronounced at a higher dose that is comparable to the dose used in humans. It should be noted that anti-VEGF-A pharmacotherapy has not been associated with an increased risk of profound retinal damage in humans 33 , but subtle abnormalities have been observed 34, 35 and some adverse effects might be misattributed to disease progression. In contrast to VEGF-A blockade, neither an anti-CCR3 antibody nor a CCR3 receptor antagonist induced retinal toxicity in wild-type mice, as confirmed by fundus imaging and electrophysiological function ( Supplementary Fig. 12 ). Vegfa deletion is embryonically lethal 36, 37 and conditional ablation of Vegfa in the RPE induces profound retinal degeneration and visual dysfunction 38 . In contrast, the Ccr3 2/2 mouse retina was normal in appearance and electrophysiological function ( Supplementary Fig. 13 ).
Discussion
Our findings suggest that CCR3 targeting may be a safe and viable strategy for early detection (using biocompatible quantum dots or other bioimaging fluorochromes, such as near infrared dyes) and treatment of CNV (by receptor or ligand targeting), and might be superior to the current standard of care. CCR3 bioimaging is probably most useful in individuals with RPE pigmentary disturbances and multiple subretinal lipoproteinaceous deposits known as drusen or fellow eye involvement with clinically evident CNV, as they are known to be at high risk for developing CNV 39, 40 . Similar techniques might be useful in non-invasively bioimaging other metabolic or molecular markers to provide information about disease pathogenesis or activity.
Several strategies have yielded molecular markers that are preferentially expressed on proliferating endothelial cells such as those in tumour vasculature 41, 42 ; however, CCR3 has not been identified in any of these reports. Therefore, our studies identify CCR3 as a new marker of pathological angiogenesis and as a functional target in neovascular AMD. These findings should also prompt a search for genetic polymorphisms in the eotaxin-CCR3 axis in patients with AMD, and investigations of CCR3 function in other models of angiogenesis. Also, it is tempting to speculate that targeting CCR3 might provide dual benefits in asthma, which involves varying degrees of eosinophilic inflammation as well as angiogenic airway remodelling 43 .
METHODS SUMMARY
Mouse model of CNV. Laser photocoagulation (OcuLight GL, Iridex Corporation) was performed on mouse eyes to induce CNV, and CNV volumes were measured 7 days after injury by scanning laser confocal microscopy (TCS SP, Leica), as previously described 22 . Drug injections. Rat IgG2a neutralizing antibody against mouse CCR3 (R&D Systems), control rat IgG2a (Serotec), goat neutralizing antibody against mouse CCL11 (R&D Systems), goat neutralizing antibody against mouse CCL24 (R&D Systems), control goat IgG (Jackson Immunoresearch), or (S)-methyl-2naphthoylamino-3-(4-nitrophenyl)propionate (SB328437; Calbiochem) dissolved in dimethylsulphoxide (DMSO) were injected into the vitreous humour using a 33-gauge double-calibre needle (Ito Corporation) once, immediately after laser injury as previously described 22 .
CCR3 bioimaging. Fab fragments were created from monoclonal IgG2a antibody raised against the extracellular domain of murine CCR3 (R&D Systems) and an isotype rat IgG2a (R&D Systems) using a commercially available papainbased kit (Pierce). Recovered fragments were conjugated with quantum dots (Invitrogen, QDot-800) and resuspended in sterile PBS. Ccl2 2/2 Ccr2 -/mice were administered 100 mg of tagged CCR3 Fab or isotype Fab by tail-vein injection after acquiring baseline fluorescent imaging using a Topcon retinal camera (TRC-50IX). Serial images were then acquired at 1, 4 and 12 h, after which eyes were collected and frozen in OCT for immunofluorescent analyses. Retinal images were analysed (ImageNet, Topcon) by comparison to baseline and fluorescein angiographic data. Hyperfluorescent areas were then cropped, equally thresholded, and pseudocoloured (Photoshop CS3, Adobe). Sections from QDot-conjugated CCR3 or rat IgG2a isotype Fab injected animals were fixed in 4% paraformaldehyde and blocked with 5% normal donkey serum/5% goat serum in PBS, stained with rat anti-mouse CD31 (BD Biosciences) and either rabbit anti-mouse CCR3 (Santa Cruz) or rabbit anti-Ki67 (Abcam), followed by appropriate fluorescent secondary antibodies (Alexa Fluor 488/594, Invitrogen), and evaluated by confocal laser scanning microscopy (Leica SP-5).
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
